BNF for Children (BNFC) 2018-2019
Sulfonamides(continued) ▶Antimalarials(pyrimethamine)increase the risk of side-effects when given withsulfonamides.rStudy→Also s ...
▶Clindamycinincreases the effects ofsuxamethonium.r Anecdotal ▶Corticosteroidsare predicted to decrease the effects of suxametho ...
Tacrolimus(continued) ▶Antifungals, azoles(miconazole)are predicted to increase the concentration oftacrolimus. Monitor and adju ...
▶Crizotinibis predicted to increase the exposure tocabazitaxel. oTheoretical→Also seeTABLE 15p. 850 ▶Efavirenzis predicted to de ...
Temsirolimus(continued) ▶HIV-protease inhibitorsare predicted to increase the concentration oftemsirolimus. Avoid.rTheoretical ▶ ...
irreversible. Avoid and for 14 days after stopping the MAOI. rTheoretical Tetracaine→see anaesthetics, local Tetracycline→see te ...
Theophylline(continued) ▶Valacicloviris predicted to increase the exposure to theophylline.rTheoretical Thiazide diuretics→seeTA ...
▶Antiepileptics(fosphenytoin, phenytoin)moderately decrease the exposure totizanidine.nStudy ▶Combined hormonal contraceptivesin ...
Tolvaptan(continued) ▶Crizotinibis predicted to increase the exposure totolvaptan. Adjust dose.oStudy ▶Tolvaptanincreases the co ...
Trandolapril→see ACE inhibitors Tranexamic acid→seeTABLE 5p. 847 (thromboembolism) Tranylcypromine→see monoamine-oxidase A and B ...
Trimethoprim(continued) ▶Trimethoprimincreases the concentration ofantiepileptics (fosphenytoin, phenytoin).oStudy ▶Antimalarial ...
Vancomycin→seeTABLE 2p. 847 (nephrotoxicity),TABLE 19p. 851 (ototoxicity) Vandetanib→seeTABLE 9p. 849 (QT-interval prolongation) ...
Venetoclax(continued) ▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)are predicted to decrease ...
▶Enzalutamideis predicted to decrease the exposure tovinca alkaloids(vinblastine, vincristine, vindesine).rTheoretical ▶Enzaluta ...
Voxilaprevir(continued) ▶HIV-protease inhibitors(atazanavir)(boosted with ritonavir) increase the concentration ofvoxilaprevir. ...
▶Macrolides(clarithromycin)are predicted to increase the exposure tozopiclone. Adjust dose.oTheoretical ▶Macrolides(erythromycin ...
Appendix Borderline substances CONTENTS Enteral feeds (non-disease specific) page 1014 Enteral feeds (non-disease specific): les ...
Covermark®classic foundation andfinishing powder; Dermablend®Ultracorrective foundation;Dermacolor® Camouflage cream andfixing p ...
Table 1 Enteral feeds (non-disease specific) Less than 5 g protein/100 mL Enteral feeds: 1 kcal/mL and less than 5 g protein/100 ...
SOYA PROTEIN FORMULA Product Formulation Energy Protein Carbohydrate Fat Fibre Special Characteristics ACBS Indications Presenta ...
«
47
48
49
50
51
52
53
54
55
56
»
Free download pdf